Skip to main
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio Inc. has demonstrated consistent clinical benefits in patients receiving RGX-202 treatment, with improvements observed at 9 and 12 months that favorably compare to natural history data, indicating strong therapeutic potential. The company has also shown durable treatment effects from its therapy sura-vec, with stable or improved vision up to four years, suggesting long-term efficacy in target diseases. Additionally, the scalable manufacturing capabilities of Regenxbio position it favorably for potential revenue generation, while the encouraging interim data from the AFFINITY DUCHENNE trial further strengthen the outlook for the company's gene therapy pipeline.

Bears say

Regenxbio Inc faces significant risks related to potential delays in data releases, which could adversely influence investor sentiment and prompt downward revisions of revenue estimates. The challenges associated with developing adequate manufacturing capacity for its complex AAV-based gene therapies could further constrain financial forecasts and hinder product commercialization efforts. Additionally, the possibility of regulatory setbacks stemming from safety concerns poses an ongoing risk that may negatively impact the company’s future performance in the gene therapy market.

REGENXBIO (RGNX) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 8 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.